Precipio Inc

Precipio Inc(PRPO)资讯与事件

$28.850

-0.433 (-1.50%)收盘时

PRPO 资讯

PRPO 事件

5/14 17:10

Precipio CEO Highlights Continued Growth in Business Fundamentals

"I think this quarter is a good example of how to properly assess non-commercial fluctuations in our business," said Ilan Danieli, CEO of Precipio. "While revenue is flat, that is largely a function of timing. The underlying business fundamentals continue to grow, in particular the product pipeline that has been generated by our newly hired commercial team."

3/10 09:10

Precipio Launches New Assay for Chronic Myeloid Leukemia

Precipio has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, CML. Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all four clinically important variants of BCR::ABL1 (isoforms). Precipio is first to apply the International Scale to create a novel assay quantifying all four variants, setting a new standard for monitoring patients with CML. Now, for the first time, clinicians can comprehensively monitor disease progression."

2/25 09:40

Ilan Danieli: Company Value Tripled in 2025

"Becoming an EBITDA and cash-flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a longer-term perspective for the Company, rather than a constant focus on short-term cash burn considerations." said Ilan Danieli, CEO. "2025 was a great year for us, one where the business performed well, and shareholders saw their value triple. We are confident in our ability to continue to create this value."

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始